Hormonal

Long-acting GLP-1 receptor agonists (dulaglutide, liraglutide, once-weekly exenatide) provide superior glycemic control (HbA1c and FPG reduction) compared to short-acting agents (EBID, lixisenatide) in type 2 diabetes patients.

If you have Type 2 Diabetes and need better blood sugar control, long-acting GLP-1 medications (like dulaglutide, liraglutide, or once-weekly exenatide) are more effective at lowering HbA1c and fasting glucose than short-acting versions (like twice-daily exenatide or lixisenatide). Choose a long-acting option for superior glycemic results, keeping in mind that all GLP-1s carry a risk of gastrointestinal side effects.